) The purpose of this component of the SPORE in Ovarian Cancer is to recruit and develop new faculty with a major commitment to translational research in ovarian cancer. It is anticipated that these new faculty members will not only develop expertise in their own relevant basic and/or clinical ovarian cancer research, but, through sound mentoring, will also develop into productive translational researchers. Thus, a major factor in recruitment will be a demonstrated or anticipated ability to communicate ideas among basic and clinical scientists within the programs. It is anticipated that progressive responsibility will be given to these individuals to prepare them for institutional and national leadership in the development of effective strategies to reduce the incidence and mortality of ovarian cancer. We have allocated $200,000 per year for this purpose and will allocate $50,000 annually for salary support of individuals in this area. In addition, we have institutional commitments of $200,000 from the Howard Hughes Career Development Award funding that will be applied to further salary support of key recruits. One clear need for this program is a molecular geneticist with a keen interest in genetic causes of cancer, particularly ovarian cancer. With the construction of the Genetics Building and establishment of the Herin Genetics Center, it is our intent to use the Howard Hughes Career Development Award to recruit a molecular geneticist to play a major role in this SPORE in Ovarian Cancer. We expect to identify recipients for these awards from several sources, both internal and external: 1. Individuals who have been training (doctoral or post-doctoral) in the laboratories or clinical units of the Comprehensive Cancer Center and have demonstrated the ability to complement or expand the research activities of this SPORE in Ovarian Cancer. These individuals must be ready to assume a junior faculty position and be committed to ovarian cancer research. 2. Basic or clinically trained individuals from other institutions who are at the junior or mid-faculty level and have been identified by members of the SPORE as potentially important contributors to translational research within the SPORE in Ovarian Cancer. 3. Junior or mid-level faculty within our own institution who have shown exceptional translational basic or clinical expertise in other relevant cancers and have an interest in changing the focus of their career to this area. This mechanism will not be used for recruitment of senior faculty, which will continue to be the responsibility of the individual department chairs or university-wide centers. Neither will this mechanism be used to support postdoctoral positions which will continue to be the responsibility of individual investigators, departments and programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA083591-04S1
Application #
6662781
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-30
Project End
2003-09-29
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Skates, Steven J; Greene, Mark H; Buys, Saundra S et al. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res 23:3628-3637
Ren, Yi A; Mullany, Lisa K; Liu, Zhilin et al. (2016) Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones. Cancer Res 76:2206-18
Nelson, Carol A; Azure, Michael T; Adams, Christopher T et al. (2014) The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med 55:2020-5
Kim, Kenneth H; Dmitriev, Igor; O'Malley, Janis P et al. (2012) A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin Cancer Res 18:3440-51
Kimball, Kristopher J; Preuss, Meredith A; Barnes, Mack N et al. (2010) A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res 16:5277-87
Borovjagin, Anton V; McNally, Lacey R; Wang, Minghui et al. (2010) Noninvasive monitoring of mRFP1- and mCherry-labeled oncolytic adenoviruses in an orthotopic breast cancer model by spectral imaging. Mol Imaging 9:59-75
Szafran, April Adams; Folks, Karri; Warram, Jason et al. (2009) Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis. Cancer Biol Ther 8:1109-16
Matsumura, Noriomi; Huang, Zhiqing; Baba, Tsukasa et al. (2009) Yin yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res 7:210-20
Bell, Walter C; Sexton, Katherine C; Grizzle, William E (2009) How to efficiently obtain human tissues to support specific biomedical research projects. Cancer Epidemiol Biomarkers Prev 18:1676-9
Meredith, Ruby F; Shen, Sui; Forero, Andres et al. (2008) A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae. J Nucl Med 49:279-84

Showing the most recent 10 out of 114 publications